Multiple Independent Molecular Signals Converge to Validate GRI-0621 as a Potential Disease-Modifying TherapyLA JOLLA, CA, (GLOBE ...
About MyPath® Melanoma MyPath Melanoma is Castle’s gene expression profile test designed to provide an accurate, objective result to aid dermatopathologists and dermatologists in characterizing ...
The NCCN guidelines now include MammaPrint for identifying HR+/HER2- early-stage breast cancer patients who may benefit from ...
Across primary sites, histological subtypes, and mitotic count categories, clinicopathological factors and gene-expression profile results were consistent for discriminating SLN positivity rates.
Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology Conference - Hawaii® ...
Using genomic and transcriptional data has greatly improved the understanding of multiple aspects of human physiology. A new paper in PNAS reports on molecular-level associations of co-occurring ...
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today provided an update on its test ...
Why do some tumors spread while others remain localized? The mechanisms governing the metastatic potential of tumor cells ...
In modern functional genomics, understanding how specific genes control cellular behavior requires both targeted intervention and high-resolution analysis. That’s where Perturb-Seq comes in—a method ...
UCSF researchers identified 30 transcription factors that reverse age-related gene expression in fibroblasts. Using CRISPR to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results